Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Accumulated Depreciation data on record, last reported at $9.6 million in Q2 2025.

  • For Q2 2025, Accumulated Depreciation rose 53.84% year-over-year to $9.6 million; the TTM value through Jun 2025 reached $9.6 million, up 53.84%, while the annual FY2024 figure was $7.7 million, 52.57% up from the prior year.
  • Accumulated Depreciation reached $9.6 million in Q2 2025 per CRNX's latest filing, up from $8.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $9.6 million in Q2 2025 and bottomed at $3.0 million in Q1 2021.
  • Average Accumulated Depreciation over 5 years is $5.6 million, with a median of $5.0 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 62.02% in 2021, then grew 17.36% in 2022.
  • A 5-year view of Accumulated Depreciation shows it stood at $3.5 million in 2021, then grew by 17.36% to $4.1 million in 2022, then rose by 24.09% to $5.1 million in 2023, then skyrocketed by 52.57% to $7.7 million in 2024, then rose by 23.98% to $9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $9.6 million in Q2 2025, $8.6 million in Q1 2025, and $7.7 million in Q4 2024.